Skip to main content

Table 3 Biological pathways displaying down-regulation (compared with normal mucosa) in SPLs, LPLs, and CRCs

From: Molecular pathways undergoing dramatic transcriptomic changes during tumor development in the human colon

   Nominal p-values of enrichment scores †
Pathways n * N vs SPL N vs LPL N vs CRC
1) BIOCARTA AT1R PATHWAY 50 0.047 - -
2) BIOCARTA BIOPEPTIDES PATHWAY 81 0.027 - -
3)BIOCARTA IL3 PATHWAY 20 0.044 - -
4) KEGG ALDOSTERONE REGULATED SODIUM REABSORPTION 51 0.029 - -
5) KEGG CHEMOKINE SIGNALING PATHWAY 216 0.042 - -
6) KEGG GAP JUNCTION 100 0.039 - -
7) KEGG MAPK SIGNALING PATHWAY 400 0.047 - -
8) KEGG VASCULAR SMOOTH MUSCLE CONTRACTION 152 0.037 - -
9) REACTOME FORMATION OF PLATELET PLUG 236 0.017 - -
10) REACTOME FRS2 MEDIATED ACTIVATION 23 0.049 - -
11) REACTOME HEMOSTASIS 348 0.024 - -
12) REACTOME METABOLISM OF LIPIDS AND LIPOPROTEINS 256 0.046 - -
13) REACTOME NRAGE SIGNALS DEATH THROUGH JNK 61 0.041 - -
14) REACTOME PLATELET ACTIVATION 208 0.018 - -
15) REACTOME RHO GTPASE CYCLE 132 0.046 - -
16) REACTOME SEMAPHORIN INTERACTIONS 89 0.031 - -
17) SA PTEN PATHWAY 27 0.027 - -
18) REACTOME CAM PATHWAY 32 - 0.042 -
19) REACTOME G ALPHA Z SIGNALLING EVENTS 13 - 0.04 -
20) REACTOME G BETA GAMMA SIGNALLING THROUGH PLC BETA 23 - 0.037 -
21) REACTOME G PROTEIN ACTIVATION 34 - 0.02 -
22) REACTOME NEURORANSMITTER RECEPTOR BINDING AND DOWNSTREAM TRANSMISSION IN THE POSTSYNAPTIC CELL 115 - 0.035 -
23) BIOCARTA NUCLEARRS PATHWAY 22 - - 0.009
24) KEGG ASCORBATE AND ALDARATE METABOLISM 19 - - 0.008
25) KEGG DRUG METABOLISM CYTOCHROME P450 71 - - 0.017
26) KEGG DRUG METABOLISM OTHER ENZYMES 51 - - 0.045
27) KEGG LONG TERM POTENTIATION 94 - - 0.024
28) KEGG METABOLISM OF XENOBIOTICS BY CYTOCHROME P450 69 - - 0.018
29) KEGG NICOTINATE AND NICOTINAMIDE METABOLISM 26 - - 0.047
30) KEGG PENTOSE AND GLUCURONATE INTERCONVERSIONS 24 - - 0.009
31) KEGG NITROGEN METABOLISM 28 - - 0.024
32) KEGG RETINOL METABOLISM 59 - - 0.028
33) KEGG STARCH AND SUCROSE METABOLISM 54 - - 0.014
34) REACTOME ACTIVATION OF NMDA RECEPTOR UPON GLUTAMATE BINDING AND POSTSYNAPTIC EVENTS 62 - - 0.049
35) REACTOME ETHANOL OXIDATION 8 - - 0.012
36) REACTOME GLUCURONIDATION 15 - - 0
37) REACTOME MITOCHONDRIAL FATTY ACID BETA OXIDATION 9 - - 0.039
38) REACTOME PHASE II CONJUGATION 62 - - 0.036
39) BIOCARTA HDAC PATHWAY 44 0.022 0.041 -
40) KEGG GLYCOSPHINGOLIPID BIOSYNTHESIS LACTO AND NEOLACTO SERIES 37 0.041 0.037 -
41) REACTOME ACTIVATION OF KAINATE RECEPTORS UPON GLUTAMATE BINDING 37 0.022 0.01 -
42) REACTOME ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 1 31 0.01 0.01 -
43) REACTOME ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 12 24 0.028 0.021 -
44) REACTOME GLUCAGON SIGNALING IN METABOLIC REGULATION 42 0.046 0.028 -
45) REACTOME GLUCAGON TYPE LIGAND RECEPTORS 39 0.042 0.036 -
46) REACTOME GS ALPHA MEDIATED EVENTS IN GLUCAGON SIGNALLING 30 0.015 0.012 -
47) REACTOME G BETA GAMMA SIGNALLING THROUGH PI3KGAMMA 30 0.034 0.027 -
48) REACTOME HORMONE SENSITIVE LIPASE HSL MEDIATED TRIACYLGLYCEROL HYDROLYSIS 18 0.045 0.042 -
49) REACTOME IONOTROPIC ACTIVITY OF KAINATE RECEPTORS 14 0.049 0.018 -
50) REACTOME OTHER SEMAPHORIN INTERACTIONS 25 0.005 0.005 -
51) REACTOME PLATELET ACTIVATION TRIGGERS 73 0.028 0.047 -
52) REACTOME SIGNAL AMPLIFICATION 39 0.007 0.005 -
53) REACTOME THROMBIN SIGNALLING THROUGH PROTEINASE ACTIVATED RECEPTORS 28 0.019 0.016 -
54) REACTOME THROMBOXANE SIGNALLING THROUGH TP RECEPTOR 26 0.007 0.003 -
55) KEGG GNRH SIGNALING PATHWAY 150 0.017 - 0.008
56) BIOCARTA STATHMIN PATHWAY 34 - 0.034 0.009
57) BIOCARTA PGC1A PATHWAY 37 0.005 0.011 0.008
58) KEGG PPAR SIGNALING PATHWAY 86 0.026 0.034 0.044
59) KEGG PROXIMAL TUBULE BICARBONATE RECLAMATION 25 0.003 0.003 0.011
60) KEGG SULFUR METABOLISM 18 0.047 0.03 0.038
61) REACTOME NUCLEAR RECEPTOR TRANSCRIPTION PATHWAY 78 0.005 0.006 0.006
62) REACTOME NUCLEOTIDE LIKE PURINERGIC RECEPTORS 23 0.011 0.012 0.022
63) REACTOME P2Y RECEPTORS 18 0.009 0.01 0.036
  1. * n = number of RefSeqs in the pathway.
  2. † measured by RS analysis; only significant p-values (< 0.05) are shown.